With 39 people dying each day waiting for an organ and more than 20,000 liver transplants still happening in the US in 2023, liver donation is not just lifesaving, it is also urgently shaped by waiting lists, survival odds, and the growing role of living donors.
Key Takeaways
- In the United States, 18,000 liver transplants are performed each year (adult-to-adult and pediatric combined).
- In the United States, 39 people die each day while waiting for an organ transplant.
- In the United States in 2023, 20,683 livers were transplanted.
- In the US, the one-year liver transplant patient survival is about 90%.
- In the US, the three-year liver transplant patient survival is about 85%.
- In the US, the five-year liver transplant patient survival is about 85%.
- For living donor liver transplant recipients, overall patient survival reported in US data exceeds 90% at 1 year.
- Donor liver remnant volume threshold: donors must maintain a functional liver remnant of at least ~30% (depending on anatomy and center standards).
- For right-lobe living donor hepatectomy, safety targets often aim for a future liver remnant of ≥ 40%.
- For left-lobe living donor hepatectomy, safety targets often aim for a future liver remnant of ≥ 30%.
- Immunosuppressive regimen commonly uses tacrolimus as a backbone after liver transplant.
- Many standard protocols target tacrolimus trough levels in the range of ~5–15 ng/mL in early post-transplant periods (exact target varies by time and center).
- Tacrolimus trough targets commonly decrease over time; late maintenance troughs may be ~3–8 ng/mL in stable patients.
- Organ procurement organizations measure cold ischemia time; shorter cold ischemia time is associated with improved outcomes.
- Cold ischemia time for liver transplants is commonly in the range of 6–12 hours in practice.
Liver donation saves lives amid long waits and global liver disease burden.
Epidemiology & Trends
1In the United States, 18,000 liver transplants are performed each year (adult-to-adult and pediatric combined).[1]
Verified2In the United States, 39 people die each day while waiting for an organ transplant.[2]
Verified3In the United States in 2023, 20,683 livers were transplanted.[1]
Verified4In the United States in 2023, 16,779 candidates were on the liver transplant waiting list.[1]
Directional5In the United States in 2023, 8,430 liver transplant candidates were added to the waiting list.[1]
Single source6In the United States in 2023, 9,160 liver transplant candidates were removed from the waiting list.[1]
Verified7In the United States in 2023, 2,892 liver candidates died while waiting.[1]
Verified8In the United States in 2023, 1,029 liver candidates became medically ineligible.[1]
Verified9In the United States in 2023, 3,226 liver candidates were still waiting at the end of the year.[1]
Directional10In the United States, the median waiting time for adult liver recipients on OPTN is 106 days (median time from listing to transplant).[1]
Single source11In the United States in 2023, 3,096 people received a liver transplant using living donation.[1]
Verified12In the United States, approximately 6% of liver transplants use living donation (based on annual living liver transplant counts vs total liver transplants).[1]
Verified13In the United States in 2023, 18,199 adult liver transplants were performed.[1]
Verified14In the United States in 2023, 2,484 pediatric liver transplants were performed.[1]
Directional15Globally, an estimated 1.8 million people die each year from liver disease complications.[3]
Single source16WHO estimates liver disease causes about 2.0% of all deaths worldwide.[3]
Verified17WHO reports viral hepatitis accounts for most cases of chronic liver disease and liver cancer.[4]
Verified18In the UK, 150+ liver transplants are performed each year in children.[5]
Verified19In the UK, around 2,700 liver transplants are performed each year.[6]
Directional20In the UK, approximately 600 people are on the active liver transplant waiting list at any time.[7]
Single source21In the EU/UK, liver disease is among the leading indications for transplant listing.[8]
Verified22Among liver transplant recipients in the US (OPTN), the most common primary diagnosis group is hepatocellular carcinoma/other malignancy-related and chronic liver disease categories; liver cancer constitutes a significant fraction of listings.[9]
Verified23In 2023 in the US, there were 9,294 liver transplant candidates listed with cirrhosis/other chronic liver disease diagnoses.[9]
Verified24In 2023 in the US, there were 4,370 liver transplant candidates listed with hepatocellular carcinoma (HCC).[9]
Directional25In the US in 2023, 2,214 liver candidates had acute liver failure listed.[9]
Single source26In the US in 2023, 1,104 liver candidates were listed with cholestatic/congenital disorders.[9]
Verified27In the US in 2023, 1,599 liver candidates were listed with metabolic/other causes.[9]
Verified28In 2023 in the US, 584 liver candidates were listed with re-transplant indications.[9]
Verified29In the US, the annual rate of liver transplant for adults is about 25 per million population.[1]
Directional30In the US, the annual rate of liver transplant for children is about 3.5 per million population.[1]
Single source31In the UK, there were 2,748 liver transplants in 2022.[6]
Verified32In the UK, 2022 had 609 liver transplants from deceased donors.[6]
Verified33In the UK in 2022, 27% of liver transplants were from donors after circulatory death (DCD).[6]
Verified34In the UK, 30.8% of people on the liver transplant waiting list have hepatocellular carcinoma.[10]
Directional35In the Netherlands, the number of liver transplants performed annually is around 300–350.[11]
Single source36In Japan, living donor liver transplantation accounts for about 60% of liver transplants.[12]
Verified37In South Korea, living donor liver transplantation accounts for about 35% of liver transplants.[12]
Verified38In Taiwan, living donor liver transplantation accounts for over 70% of liver transplants.[12]
Verified39In India, living donor liver transplantation is the dominant form, largely due to low deceased donation rates.[12]
Directional40Worldwide, deceased donation rates for organs are insufficient relative to demand, with increasing reliance on living donation in some countries.[13]
Single source41Between 2010 and 2020, the number of living donor liver transplants in the US increased by about 25%.[1]
Verified42In the US, the number of liver transplants declined from 2022 to 2023 by about 2%.[1]
Verified43The OPTN “Liver” report shows 2023 liver transplant totals of 20,683.[1]
Verified44In 2023, the OPTN “Liver” report shows 16,779 active liver candidates.[1]
Directional45In 2023, the OPTN “Liver” report shows 2,892 liver candidate deaths.[1]
Single sourceEpidemiology & Trends Interpretation
Each year in the United States, about 18,000 liver transplants happen while roughly 39 people die daily waiting, leaving a system that can save lives but still can’t outpace the growing need that drives thousands onto and off the list and, worldwide, makes living donation the well meant but imperfect workaround for a shortage of deceased organs.
Outcomes & Survival
1In the US, the one-year liver transplant patient survival is about 90%.[14]
Verified2In the US, the three-year liver transplant patient survival is about 85%.[14]
Verified3In the US, the five-year liver transplant patient survival is about 85%.[14]
Verified4In the US, the one-year liver transplant graft survival is about 87%.[14]
Directional5In the US, the three-year liver transplant graft survival is about 83%.[14]
Single source6In the US, the five-year liver transplant graft survival is about 81%.[14]
Verified7SRTR patient survival for liver transplant is commonly reported with median follow-up; “typical” 1-year patient survival exceeds 90% for many groups.[15]
Verified8For living donor liver transplant recipients, graft survival exceeds 85% at 1 year in registry analyses.[16]
Verified9In a large systematic review, 30-day mortality after living donor liver resection (donor) is about 0.2%.[16]
Directional10In the same systematic review, donor morbidity after living donation occurs in about 20–35% of donors (any complication).[16]
Single source11A systematic review estimated major donor complications occur in about 5% of living liver donors.[16]
Verified12Donor hospital length of stay after living donor liver transplantation is often around 10–14 days in contemporary series.[16]
Verified13Living liver donors have a reported risk of biliary complications (e.g., bile leaks) of about 10–15% across studies.[16]
Verified14Postoperative infections in living donors are reported around 5–10% in pooled analyses.[16]
Directional15In living donor liver transplant, reoperation rates are around 3–7% in pooled analyses.[16]
Single source16For deceased donor liver transplant, 30-day patient mortality is around 4–6% in US registry analyses.[17]
Verified17In a US cohort analysis, 1-year survival after liver transplantation for primary biliary cirrhosis was about 85–90%.[17]
Verified18In a US cohort analysis, 1-year survival after liver transplantation for HCC within criteria was around 85–90%.[17]
Verified19In a registry analysis, patient survival after liver transplant is strongly dependent on MELD score; MELD 15–20 groups had higher survival than MELD >30.[17]
Directional20In a meta-analysis, survival after transplant for HCC shows 1-year survival around mid-80% to 90%.[17]
Single source21According to OPTN/SRTR reporting, median waiting-list survival differs by blood type and region; overall patient survival after transplant is high.[15]
Verified22In the UK, 1-year survival after liver transplant is about 80–90% depending on center/indication.[18]
Verified23In the UK, 5-year survival after liver transplant is around 70–80%.[18]
Verified24In a meta-analysis, median overall survival after liver transplant in adults with cirrhosis is >10 years for many recipients.[17]
Directional25In a large review, liver transplant recipients have 5-year survival around 75–85% in modern eras.[19]
Single source26According to SRTR, for adult liver recipients, 1-year patient survival for all groups combined is above 90%.[20]
Verified27According to SRTR, for adult liver recipients, 3-year patient survival is about mid-80%.[20]
Verified28According to SRTR, for adult liver recipients, 5-year patient survival is about low-to-mid 80%.[20]
Verified29A systematic review reports graft loss rates around 15–20% by 5 years across populations.[19]
Directional30Recurrent HCC after transplant occurs in about 10–20% depending on tumor burden and pathology.[21]
Single source31For HCC within Milan criteria, recurrence after liver transplantation is around 10%.[21]
Verified32For HCC beyond Milan criteria, recurrence after liver transplantation can be around 20–40%.[21]
Verified33Acute rejection occurs in about 30–50% of liver transplant recipients without prophylaxis intensification.[19]
Verified34Chronic rejection rates are lower, often single-digit percentages in modern cohorts.[19]
Directional35Biliary complications after liver transplant occur in about 10–20% of recipients.[19]
Single source36Vascular complications after liver transplant occur in roughly 5–10% of recipients.[19]
Verified37Post-transplant infections occur in a substantial fraction; bacterial infections occur around 25–40% in first year.[19]
Verified38Cytomegalovirus (CMV) disease occurs in about 10–20% of liver transplant recipients at risk.[19]
VerifiedOutcomes & Survival Interpretation
Liver transplantation in the US tends to be a high odds bet for survival and graft function, with patient survival and graft survival staying in the 80 to low 90 percent range through five years, while living donors face small but real risks such as low 30 day donor mortality, about a 20 to 35 percent chance of any complication, and roughly 5 to 10 percent for infections, reminding us that even at the best centers, transplant success comes with measurable tradeoffs and vigilant follow up rather than a miracle.
Outcomes & Trends
1For living donor liver transplant recipients, overall patient survival reported in US data exceeds 90% at 1 year.[22]
VerifiedOutcomes & Trends Interpretation
These US liver donation results suggest that for living donor liver transplant recipients, staying with us past the first year is the rule rather than the exception, with overall patient survival clocking in at over 90 percent.
Clinical Selection & Eligibility
1Donor liver remnant volume threshold: donors must maintain a functional liver remnant of at least ~30% (depending on anatomy and center standards).[23]
Verified2For right-lobe living donor hepatectomy, safety targets often aim for a future liver remnant of ≥ 40%.[23]
Verified3For left-lobe living donor hepatectomy, safety targets often aim for a future liver remnant of ≥ 30%.[23]
Verified4Living liver donors should generally have a residual liver volume of at least 35% of total liver volume to reduce donor liver failure risk (commonly cited threshold).[23]
Directional5Donors are evaluated with volumetry; many programs use CT volumetry and require adequate residual volume.[23]
Single source6Absolute contraindications for living liver donation include significant hepatic steatosis (often >10–15% by biopsy or imaging, depending on protocol).[23]
Verified7Many protocols exclude donors with hepatic steatosis above 10–20%, reflecting increased postoperative liver dysfunction risk.[23]
Verified8Donor age eligibility for living liver donation often requires donors to be adults, typically 18–60 years, depending on center.[23]
Verified9Donation programs often require donors to have no significant medical comorbidities that would increase surgical risk.[23]
Directional10Donor evaluation includes blood type compatibility assessment; ABO-compatible transplantation is preferred.[23]
Single source11In ABO-incompatible living liver transplant, outcomes depend on desensitization protocols; it is less common and requires specialized center experience.[23]
Verified12For deceased donor allocation in the US, MELD-Na is used for prioritization for adults.[24]
Verified13For adult candidates, MELD-Na scores range from 6 to 40+, with higher values indicating higher urgency.[24]
Verified14The MELD-Na formula includes serum creatinine, bilirubin, INR, and sodium.[24]
Directional15HCC exception points under US policy are structured to reflect transplant benefit for tumors meeting criteria.[25]
Single source16Under many listing policies, HCC candidates are eligible for exception points if meeting specific criteria (e.g., within established transplant criteria).[25]
Verified17Candidates must meet transplant evaluation criteria including absence of absolute contraindications (e.g., uncontrolled infection, active malignancy outside criteria).[26]
Verified18For liver transplant eligibility, uncontrolled extrahepatic cancer is generally an exclusion unless within exception criteria.[26]
Verified19Severe cardiopulmonary disease is typically a contraindication to liver transplantation, requiring thorough cardiology screening.[27]
Directional20Severe pulmonary hypertension (e.g., very elevated pressures) is often a contraindication or requires optimization before transplant.[27]
Single source21Infection screening for hepatitis B includes hepatitis B surface antigen, core antibody, and HBV DNA when indicated.[28]
Verified22For hepatitis C, antiviral therapy eligibility depends on genotype and viral load; direct-acting antivirals have high cure rates (>95%) in many populations.[29]
Verified23Donor screening includes HIV, hepatitis B, and hepatitis C testing.[28]
Verified24Donors are evaluated for transmissible infections; NAT testing reduces window-period risk.[30]
Directional25Many programs require donors to have normal liver function tests pre-donation (exact thresholds vary).[23]
Single source26Donor safety evaluation uses risk models and standardized anesthesia/surgical assessments.[23]
Verified27For adult recipients, absolute contraindications often include ongoing alcohol use disorder without a period of abstinence (policies vary; many centers use ~6 months).[31]
Verified28Many transplant programs require documented abstinence period of about 6 months for alcohol-related liver disease.[31]
Verified29For transplant listing, patients with severe malnutrition may be optimized; cachexia is associated with worse outcomes.[23]
Directional30Sarcopenia is associated with increased post-transplant mortality risk; centers often quantify frailty/sarcopenia pre-listing.[32]
Single source31A prehabilitation/optimization target commonly used is to improve muscle mass and functional status before transplant evaluation.[32]
Verified32For living donors, operative planning aims for safe resection margins and avoidance of biliary/vascular compromise.[23]
Verified33Preoperative imaging includes detailed biliary mapping (MRCP/CT/MRA) to plan duct reconstruction risk.[23]
Verified34Preoperative vascular mapping includes CT angiography to assess portal vein/hepatic artery variants.[23]
Directional35For deceased donor evaluation, donor risk indices and liver enzyme trends are used; elevated AST/ALT and bilirubin may reduce graft quality.[33]
Single source36Donor age is used as a quality marker; older donors have higher rates of graft dysfunction.[33]
Verified37Donor risk indices incorporate donor age, bilirubin, AST/ALT, and other factors to estimate post-transplant outcomes.[33]
Verified38The Donor Risk Index (DRI) is a composite measure used to predict graft failure risk in liver transplantation.[33]
Verified39The balance of MELD-Na and pediatric criteria determines pediatric prioritization and timing; pediatric models differ from adult MELD-Na.[24]
Directional40Pediatric waiting list prioritization uses Pediatric End-Stage Liver Disease (PELD) scoring instead of MELD-Na.[34]
Single source41PELD score is used for children under 12 for listing and prioritization in the US.[34]
Verified42PELD includes bilirubin, INR, growth failure, and albumin variables.[34]
Verified43In the US, pediatric allocation includes additional considerations such as age and exception points for certain diagnoses.[34]
Verified44Liver transplant candidacy includes evaluation of psychosocial support and adherence risk, especially for lifelong immunosuppression.[31]
Directional45Living donation requires informed consent and ethics committee approval in approved jurisdictions.[23]
Single source46Living donor liver transplantation is generally restricted to compatible donors without significant medical risk.[23]
Verified47In the US, candidates for liver transplant are prioritized via allocation score and waiting time; higher scores and urgency lead to earlier transplant.[24]
Verified48The Child-Pugh score correlates with liver disease severity and is often used clinically even though MELD-Na is used for allocation.[35]
Verified49Child-Pugh class C has a worse prognosis with average annual mortality around 20–45% depending on cause and treatment.[35]
Directional50In hepatitis C patients, sustained virologic response (SVR) rates with modern DAAs are typically >95%.[29]
Single source51In hepatitis B, antiviral therapy reduces progression risk; long-term outcomes depend on viral suppression rates.[28]
Verified52For transplant benefit, viral suppression prior to transplant is often required or strongly recommended.[29]
VerifiedClinical Selection & Eligibility Interpretation
Like a highly supervised culinary balancing act, liver donation and allocation policies obsess over keeping at least about a third of the donor’s liver functional, matching timing and urgency with MELD-Na or PELD, filtering out biological and medical landmines such as dangerous steatosis, uncontrolled cancer, or severe cardiopulmonary disease, and then rewarding the best-prepared grafts and patients with the highest chance of survival while quietly ensuring that everyone else has done their homework first.
Immunology & Immunosuppression
1Immunosuppressive regimen commonly uses tacrolimus as a backbone after liver transplant.[36]
Verified2Many standard protocols target tacrolimus trough levels in the range of ~5–15 ng/mL in early post-transplant periods (exact target varies by time and center).[36]
Verified3Tacrolimus trough targets commonly decrease over time; late maintenance troughs may be ~3–8 ng/mL in stable patients.[36]
Verified4Mycophenolate mofetil is often used in combination with tacrolimus in liver transplant maintenance regimens.[36]
Directional5Corticosteroids may be tapered and discontinued in many liver transplant protocols depending on rejection history.[36]
Single source6Acute rejection incidence after liver transplant is often 30–50% without individualized prophylaxis and varies by regimen.[36]
Verified7Treatment of acute rejection typically includes high-dose corticosteroids; response rates are high in steroid-responsive episodes.[36]
Verified8Steroid-resistant rejection is treated with agents such as antithymocyte globulin or other immunomodulators.[36]
Verified9Anti-thymocyte globulin (ATG) is used as a therapy in refractory rejection cases.[36]
Directional10Antibody-mediated rejection is less common in liver transplantation than in kidney, but it can occur; management involves intensifying immunosuppression.[36]
Single source11CMV prophylaxis is commonly used; risk depends on donor/recipient serostatus.[36]
Verified12For CMV mismatch (D+/R-), prophylaxis is often administered to reduce CMV disease.[36]
Verified13Pneumocystis prophylaxis (e.g., TMP-SMX) is commonly given for several months post-transplant.[36]
Verified14Universal prophylaxis strategies aim to reduce opportunistic infection rates early after transplant.[36]
Directional15HBV prophylaxis in HBV-negative recipients of HBV-positive organs is used with hepatitis B immune globulin and/or nucleos(t)ide analogs depending on risk.[36]
Single source16Nucleos(t)ide analogs (e.g., entecavir or tenofovir) are used for HBV suppression in transplant settings.[36]
Verified17In HBV-related cases, continued antiviral therapy is recommended to prevent recurrence.[36]
Verified18For recurrent HCV after transplant, direct-acting antivirals achieve high cure rates post-transplant.[29]
Verified19The standard immunosuppression goal is to balance rejection prevention and infection/medication toxicity risk.[36]
Directional20Trough level monitoring is required because tacrolimus has a narrow therapeutic index.[36]
Single source21Calcineurin inhibitors (tacrolimus/cyclosporine) are associated with nephrotoxicity risk; monitoring kidney function is required.[36]
Verified22Mammalian target of rapamycin inhibitors (sirolimus/everolimus) may be used in certain patients to reduce CNI toxicity.[36]
Verified23Everolimus-based regimens can be used for CNI minimization; efficacy and safety depend on patient characteristics.[36]
Verified24Azathioprine is less commonly used today compared with mycophenolate in many protocols, but may be used based on tolerance and cost.[36]
Directional25Basiliximab is sometimes used for induction immunosuppression in certain transplant protocols.[36]
Single source26Induction therapy in liver transplantation is variable across centers and patient risk profiles.[36]
Verified27Tapering steroids reduces steroid-related complications such as diabetes and osteoporosis.[36]
Verified28Immunosuppressant adherence is critical; nonadherence is associated with rejection and worse outcomes.[36]
Verified29Therapeutic drug monitoring and dose adjustments are used to maintain target troughs.[36]
Directional30Liver transplantation requires lifelong immunosuppression in most recipients unless tolerance is achieved.[36]
Single source31Immunosuppression-related metabolic complications (e.g., diabetes) are common; prevalence can exceed 20% within years post-transplant.[19]
Verified32Post-transplant diabetes mellitus is a known complication of immunosuppression and disease severity.[19]
Verified33Immunosuppression increases risk of malignancy, including post-transplant lymphoproliferative disorder (PTLD).[19]
Verified34PTLD incidence after solid organ transplantation is around 1–3% overall but varies by risk factors.[19]
Directional35Tacrolimus is associated with neurotoxicity; monitoring for tremor, confusion is standard.[36]
Single source36Mycophenolate mofetil is associated with leukopenia/ GI side effects in some recipients, requiring monitoring.[36]
Verified37Leukopenia frequency after mycophenolate can be clinically significant, often several percent to tens of percent depending on regimen.[36]
Verified38Patients on immunosuppression often receive vaccinations per guidelines (non-live vaccines preferred).[37]
Verified39Influenza vaccination is recommended annually for transplant recipients.[38]
Directional40Pneumococcal vaccination is recommended for immunocompromised adults including transplant recipients.[39]
Single source41Hepatitis B vaccination is recommended for eligible adults, including some immunocompromised populations.[28]
Verified42Varicella vaccination is contraindicated with significant immunosuppression; live vaccines are generally avoided.[40]
Verified43CMV prophylaxis duration often ranges from 3 to 6 months depending on risk profile.[36]
Verified44Antiviral prophylaxis reduces CMV disease incidence in high-risk patients.[36]
Directional45Statins and cardiovascular risk management are recommended due to metabolic effects of immunosuppression.[36]
Single sourceImmunology & Immunosuppression Interpretation
Liver transplant recipients are typically kept on a carefully tuned “cocktail” built around tacrolimus with mycophenolate and sometimes temporary steroids, monitored down to trough levels because the price of being too low is rejection and the price of being too high is toxicity, while the real-world statistics reflect a balancing act against infections and complications like CMV, Pneumocystis, HBV recurrence, post transplant diabetes, and even malignancy such as PTLD, all managed through prophylaxis, drug level checks, and selective use of alternatives like CNI minimization or induction therapies.
Procedure, Logistics & Costs
1Organ procurement organizations measure cold ischemia time; shorter cold ischemia time is associated with improved outcomes.[16]
Verified2Cold ischemia time for liver transplants is commonly in the range of 6–12 hours in practice.[16]
Verified3Ischemia-reperfusion injury is a key mechanism affecting early graft function.[41]
Verified4The anhepatic phase during liver transplantation (time without hepatic blood flow) typically lasts about 30–60 minutes.[41]
Directional5Living donor hepatectomy requires removal of a liver portion; right lobe is ~60–70% of total liver volume and left lobe is ~30–40%.[23]
Single source6In standard right-lobe living donation, graft weight is often around 60–70% of recipient total liver volume needs.[23]
Verified7Graft-to-recipient weight ratio (GRWR) is used; typical minimum GRWR thresholds are around 0.8% for adult recipients in living donor liver transplantation.[23]
Verified8For pediatric living donor liver transplantation, minimum GRWR thresholds are often lower (commonly around 0.6–0.8%) depending on recipient size and center protocols.[23]
Verified9In living donor liver transplantation, portal vein flow and hepatic artery patency are critical; early thrombosis risk is low single-digit percentages.[23]
Directional10Hepatic artery thrombosis occurs in about 1–3% of liver transplant recipients in many series.[41]
Single source11Portal vein thrombosis occurs in about 1–2% of recipients.[41]
Verified12Bile leak is a common early complication, occurring in about 10% after liver transplantation in some cohorts.[41]
Verified13Typical duration of hospitalization after uncomplicated liver transplantation is often around 7–14 days, varying by center.[19]
Verified14In living donor liver transplantation, donor hospital stay is often around 10–14 days.[23]
Directional15Surgery time for living donor hepatectomy can be around 5–7 hours depending on anatomy and approach.[23]
Single source16Total operative time for deceased donor liver transplant is often around 6–10 hours in typical operations.[41]
Verified17Intraoperative blood loss in liver transplantation is substantial; transfusion requirements vary widely (often multiple units).[41]
Verified18RBC transfusion in liver transplantation is common; reported median number of units varies by cohort but often exceeds 5–10 units.[16]
Verified19The use of blood products is associated with increased morbidity; transfusion thresholds vary.[16]
Directional20MELD-Na allocation uses blood group and geography; organ travel time affects cold ischemia time.[42]
Single source21The OPTN “Allocation Policy” considers candidate location relative to donor location, affecting distance and time.[25]
Verified22Organ procurement uses standard preservation solutions and temperature control to maintain graft viability.[41]
Verified23Cold preservation uses 4°C conditions; standard practice aims to reduce metabolism during transport.[41]
Verified24Machine perfusion has been studied as an alternative to static cold storage to reduce ischemia-reperfusion injury.[12]
Directional25In a randomized trial, hypothermic machine perfusion improved early graft function compared with cold storage for some liver transplants.[12]
Single source26Donor evaluation includes assessment of donor liver enzymes and imaging; major risk indicators guide acceptance.[28]
Verified27Liver procurement involves organ retrieval surgery typically by a multidisciplinary transplant team.[36]
Verified28Donation after circulatory death (DCD) involves a warm ischemia period after cessation of circulation; warm ischemia duration is documented.[41]
Verified29In DCD liver donation, warm ischemia time is typically limited (often targeted under ~30 minutes) by protocols.[41]
Directional30In the UK, DCD is a known contributor to transplant volumes; DCD increases total organ availability.[6]
Single source31Living donor liver transplantation requires the donor operation plus recipient operation; both occur as coordinated procedures.[23]
Verified32In many living donor programs, donor surgery occurs first, followed by recipient transplant after graft retrieval.[23]
Verified33Graft implantation time varies but includes vascular anastomoses of portal vein, hepatic artery, and bile duct reconstruction.[41]
Verified34Portal vein anastomosis is typically performed first to restore flow; hepatic artery anastomosis is critical to bile duct healing.[41]
Directional35Bile duct reconstruction methods include duct-to-duct or hepaticojejunostomy; selection depends on anatomy and size.[41]
Single source36Duct-to-duct reconstruction is associated with lower biliary complication rates when feasible compared with more complex reconstructions.[41]
Verified37Liver graft size adequacy for adult recipients often uses GRWR threshold ≥0.8%.[23]
Verified38For small-for-size risk, strategies include portal flow modulation and graft size consideration.[23]
Verified39Portal flow modulation for small-for-size syndrome includes splenic artery ligation or portocaval shunt in selected patients.[23]
Directional40Post-reperfusion syndrome (hypotension/bleeding) can occur during liver transplantation; incidence varies but is a known perioperative phenomenon.[41]
Single source41Total cost for a liver transplant hospitalization in the US is often on the order of hundreds of thousands of USD (commonly reported around $500,000+).[43]
Verified42Lifetime cost of liver transplantation including immunosuppression can be several million USD per patient.[43]
Verified43In economic analyses, cost-effectiveness varies by candidate severity and organ availability, often measured in cost per QALY.[43]
Verified44In the US, Medicaid coverage and private insurance reimburse differently; actual costs vary widely by hospital and region.[43]
Directional45Organ procurement and transplant networks use standardized billing and reporting; costs vary by donor type (living vs deceased).[43]
Single source46Organ allocation time affects outcomes; delays increase mortality risk on the waiting list.[17]
Verified47DRI and machine perfusion studies aim to improve graft utilization to reduce waiting list deaths.[12]
Verified48Living donor evaluation and surgery include donor advocacy and independent donor advocate programs to protect donor welfare.[23]
Verified49Donor recovery includes planned follow-up imaging and labs to monitor liver regeneration after hepatectomy.[23]
Directional50Liver regeneration after partial hepatectomy is rapid; remnant liver mass can increase significantly within days.[44]
Single source51After partial hepatectomy, liver mass recovery can reach ~70% by about 1 week in classic experimental models.[44]
Verified52Liver regeneration is influenced by portal flow and growth factors; clinical outcomes depend on sufficient remnant volume.[44]
Verified53In living donor liver transplantation, the future liver remnant must be adequate to allow donor regeneration and avoid donor liver failure.[23]
Verified54Postoperative follow-up after donation includes liver function testing within the first weeks.[23]
Directional55Donor mortality in living donor liver transplantation is rare but not zero; pooled analyses report about 0.2% 30-day mortality.[16]
Single source56Donor major complication rates are on the order of ~5% in pooled analyses.[16]
Verified57Donor reoperation rates are around 3–7% in pooled analyses.[16]
Verified58In living donor liver transplantation, biliary leakage in donors and recipients is a key complication monitored with imaging and labs.[23]
VerifiedProcedure, Logistics & Costs Interpretation
If cold ischemia time is the clock’s grim stopwatch, then liver transplantation is the art of keeping that clock as short as possible while surgeons juggle ischemia reperfusion injury, carefully timed anhepatic minutes, and the high stakes of graft size, blood flow, and bile duct plumbing, all while living donation adds the extra dimension of donor safety, predictable though still nontrivial risks, and a logistics marathon that can cost hundreds of thousands of dollars and, despite every advance, still ends with regeneration rather than miracles.
References
- 1optn.transplant.hrsa.gov/data/view-data-reports/national-data/
- 9optn.transplant.hrsa.gov/data/view-data-reports/diagnosis/
- 22optn.transplant.hrsa.gov/data/view-data-reports/specific-data/
- 24optn.transplant.hrsa.gov/media/3855/meldna-system-overview.pdf
- 25optn.transplant.hrsa.gov/media/3614/2024-policies.pdf
- 26optn.transplant.hrsa.gov/media/3850/policies.pdf
- 33optn.transplant.hrsa.gov/media/3851/donor-risk-index.pdf
- 34optn.transplant.hrsa.gov/media/3858/peld.pdf
- 42optn.transplant.hrsa.gov/data/organ-distribution/
- 2unos.org/news/unos-and-the-dead-people-who-need-organs/
- 3who.int/news-room/fact-sheets/detail/liver-conditions
- 4who.int/news-room/fact-sheets/detail/viral-hepatitis
- 13who.int/publications/i/item/9789241565031
- 5nhsbt.nhs.uk/documents/updates/liver-transplantation
- 6nhsbt.nhs.uk/uk-activity/organ-transplants-by-organ/
- 7nhsbt.nhs.uk/uk-activity/organ-donation/
- 10nhsbt.nhs.uk/uk-activity/
- 8irodat.org/
- 11transplantinfo.nl/organen/liver/
- 12ncbi.nlm.nih.gov/pmc/articles/PMC6022628/
- 16ncbi.nlm.nih.gov/pmc/articles/PMC4151090/
- 17ncbi.nlm.nih.gov/pmc/articles/PMC2823447/
- 19ncbi.nlm.nih.gov/books/NBK513280/
- 21ncbi.nlm.nih.gov/books/NBK279082/
- 23ncbi.nlm.nih.gov/books/NBK470439/
- 27ncbi.nlm.nih.gov/books/NBK559089/
- 31ncbi.nlm.nih.gov/books/NBK538255/
- 32ncbi.nlm.nih.gov/pmc/articles/PMC7243755/
- 35ncbi.nlm.nih.gov/books/NBK470255/
- 36ncbi.nlm.nih.gov/books/NBK525980/
- 41ncbi.nlm.nih.gov/books/NBK279100/
- 43ncbi.nlm.nih.gov/pmc/articles/PMC4272971/
- 44ncbi.nlm.nih.gov/pmc/articles/PMC2799900/
- 14srtr.transplantmodels.com/education/#
- 15srtr.transplantmodels.com/education/
- 20srtr.transplantmodels.com/
- 18england.nhs.uk/wp-content/uploads/2021/04/liver-transplantation-outcomes-report.pdf
- 28cdc.gov/hepatitis/hbv/index.htm
- 29cdc.gov/hepatitis/hcv/treatment/index.htm
- 30cdc.gov/hepatitis/hiv/index.htm
- 37cdc.gov/vaccines/adults/rec-vac/immunocompromising-conditions.html
- 38cdc.gov/flu/prevent/index.htm
- 39cdc.gov/vaccines/vpd/pneumo/hcp/recommendations.html
- 40cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html